{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:19:38Z","timestamp":1789017578034,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013399","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000}}],"reference-count":186,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013399.pub2","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T12:58:37Z","timestamp":1602334717000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia"],"prefix":"10.1002","volume":"2020","author":[{"given":"Cecilie U","family":"Rank","sequence":"additional","affiliation":[{"name":"Department of Hematology; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Stensig","family":"Lynggaard","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Medicine; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Als-Nielsen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Chicago Medicine; Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Toft","sequence":"additional","affiliation":[{"name":"Department of Hematology; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ove Juul","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Hematology; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Leth","family":"Frandsen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Tuckuviene","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Aalborg University Hospital; Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1160\/TH04-02-0087","article-title":"Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients With haemato-oncological disease. A randomized controlled trial","volume":"92","author":"Ben Othman","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0002|cit2","unstructured":"Al Rabadi LS Luai S Olson SR Shatzel JJ Deloughery TG Hayes-Lattin B Thromboprophylaxis with fixed dose, 1mg\/kg\/day, low molecular weight heparin in adults undergoing induction with asparaginase for acute lymphoblastic leukemia. Results of a single institution cohort study Blood.\u00a0Conference: 59th Annual Meeting of the American Society of Hematology (ASH) Suppl 1 edition 2397 10.1182\/blood.V130.Suppl_1.2397.2397"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0003|cit3","first-page":"209","article-title":"A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase","volume":"76","author":"Belmonte","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0004|cit4","unstructured":"Bigliardi S Morselli M Potenza L Coluccio V Maccaferri M Paolini A Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study Haematologica S73 4"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3109\/10428194.2014.933216","article-title":"Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study","volume":"56","author":"Bigliardi","journal-title":"Leukemia & Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/10428194.2018.1519811","article-title":"Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia","volume":"60","author":"Chen","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Chen J Ngo DT Aldoss I Shayani S Pullarkat VA A retrospective analysis of the impact of antithrombin III supplementation on the incidence of pegaspargase-induced venous thromboembolism Journal of Clinical Oncology. Conference: the American Society of Clinical Oncology (ASCO) Suppl 15 edition e19006 10.1200\/JCO.2018.36.15_suppl.e19006","DOI":"10.1200\/JCO.2018.36.15_suppl.e19006"},{"issue":"11","key":"10.1002\/14651858.CD013399.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ajh.24130","article-title":"Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience","volume":"90","author":"Couturier","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0009|cit9","unstructured":"Elliott MA Wolf RC Hook CC Pruthi RK Heit JA Letendre LL Thromboembolism in adults with acute lymphoblastic leukemia (ALL) during induction with l-asparaginase (ASP)-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin (AT) in pathogenesis and prophylaxis Blood. Conference: 45th Annual Meeting of the American Society of Hematology (ASH) 11\u00a0Suppl 1 edition 878A"},{"issue":"8","key":"10.1002\/14651858.CD013399.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/10428190410001693588","article-title":"Thromboembolism in adults with acute lymphoblastic leukemia during induction with l-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin","volume":"45","author":"Elliott","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"10.1002\/14651858.CD013399.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.3109\/10428194.2016.1165815","article-title":"An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events","volume":"57","author":"Farrell","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0012|cit12","unstructured":"Fyfe A Allan J Leach M Antithrombin replacement in adults undergoing induction therapy for acute lymphoblastic leukaemia British Journal of Haematology.\u00a050th Annual Scientific Meeting of the British Society for Haematology Suppl 149 edition 46 http:\/\/dx.doi.org\/10.1111\/j.1365-2141.2010.08116-1.x"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Freixo A Chorao P Monteiro C Carvalho M Goncalves L Principe F Replacement therapy in all patients treated with l-asparaginase Research and Practice in Thrombosis and Haemostasis 401 http:\/\/dx.doi.org\/10.1002\/rth2.12012","DOI":"10.1002\/rth2.12012"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0014|cit14","unstructured":"George G Pearl N McCoy C Carlson K Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-a real world study Leukemia Research 10.1016\/j.leukres.2020.106368 32442786"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Rezazadeh A George G Pearl N McCoy C Zook F Jung B Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for all with asparaginase based regimens Blood. Conference: 60th Annual Meeting of the American Society of Hematology (ASH) Suppl 1 edition 1232 https:\/\/doi.org\/10.1182\/blood-2018-99-114597","DOI":"10.1182\/blood-2018-99-114597"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11239-017-1597-7","article-title":"The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia","volume":"45","author":"Grace","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Grose K Sen JM Morris AL DeGregory K Palkimas S Douvas MG Decrease of asparaginase induced thrombotic events with antithrombin III monitoring and repletion Blood. Conference: 60th Annual Meeting of the American Society of Hematology (ASH) Suppl 1 edition 1381 http:\/\/dx.doi.org\/10.1182\/blood-2018-99-116744","DOI":"10.1182\/blood-2018-99-116744"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1365-2141.1990.tb06336.x","article-title":"Hypercoagulability during l-asparaginase treatment: the effect of antithrombin III supplementation in vivo","volume":"74","author":"Gugliotta","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0019|cit19","unstructured":"Gugliotta L Mattioli MB Catani L Vianelli N Gianni L Cascione L Antithrombin III supportive therapy in patients treated with l-asparaginase International Society on Thrombosis and Haemostasis (ISTH) 1989 429"},{"issue":"10","key":"10.1002\/14651858.CD013399.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3324\/haematol.12948","article-title":"Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study","volume":"93","author":"Hunault-Berger","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Hunault-Berger M Gruel Y Harousseau JL Delain M Maakaroun M Bulabois CE Evolution of antithrombin (AT) and fibrinogen (Fg) levels during induction chemotherapy with l-asparaginase (asp) in adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). Clinical outcomes and use of coagulation supportive treatments: the CAPELAL study International Society on Thrombosis and Haemostasis (ISTH) Suppl 1 edition 2005","DOI":"10.1182\/blood.V104.11.4486.4486"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Hunault-Berger M Gruel Y Harousseau JL Delain M Maakaroun M Bulabois CE Evolution of antithrombin (AT) and fibrinogen (Fg) levels during induction chemotherapy with l-asparaginase (asp) in adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). Clinical outcomes and use of coagulation supportive treatments: the CAPELAL study Blood. Conference: American Society of Hematology (ASH) 4486 edition 11 10.1182\/blood.V104.11.4486.4486","DOI":"10.1182\/blood.V104.11.4486.4486"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0023|cit23","unstructured":"Lauw M Van Der Holt B Middeldorp S Biemond B Effect of preventive antithrombotic measures on thrombotic risk in adult patients treated for acute lymphoblastic leukemia Haematologica.\u00a016th Congress of the European Haematology Association (EHA) Issue 1 edition 240"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0024|cit24","unstructured":"Lauw MN Van Der Holt B Middeldorp S Meijers JC Biemond BJ Impact of prophylactic fresh frozen plasma on venous thromboembolism in adults treated for acute lymphoblastic leukemia receiving asparaginase Blood. Conference: 53rd Annual Meeting of the American Society of Hematology (ASH) Issue 21 edition 1435 6"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0025|cit25","unstructured":"Lauw MN Van der Holt B Middeldorp S Biemond BJ Effect of preventive antithrombotic measures on thrombotic risk in adult patients treated for acute lymphoblastic leukemia Journal of Thrombosis and Haemostasis.\u00a023rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) Issue 2 edition 436"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1160\/TH12-11-0845","article-title":"Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation","volume":"109","author":"Lauw","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0027|cit27","unstructured":"McCloskey JK Stanislaus G Koprivnikar JL Andrews T Elizabeth J Marcotulli D Outcomes with augmented hyper-CVAD (AHCVAD), a pediatric inspired HCVAD-based regimen, for adults younger than 50 years of age with newly diagnosed acute lymphoblastic leukemia (ALL) Blood. Conference: 59th Annual Meeting of the American Society of Hematology (ASH) 5050 https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.5050.5050"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Orvain C Balsat M Lheritier V Tavernier E Prevention of venous thrombotic events in adult patients with acute lymphoblastic leukemia treated in a pediatric-inspired protocol-a graall study Blood. Conference: 58th Annual Meeting of the American Society of Hematology (ASH) Issue 22 edition 2776 https:\/\/doi.org\/10.1182\/blood.V128.22.2776.2776","DOI":"10.1182\/blood.V128.22.2776.2776"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood.2020004919","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 Study","volume":"136","author":"Orvain","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000204081","article-title":"L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy","volume":"93","author":"Pogliani","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0031|cit31","unstructured":"Rank CU Toft N Tuckuviene R Grell K Nielsen OJ Frandsen TL Thromboembolism in ALL patients 1-45 years treated according to the NOPHO-ALL 2008 protocol Blood.\u00a0Conference: 59th Annual Meeting of the American Society of Hematology (ASH). Suppl 1 edition 2564 2564 https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.2564.2564"},{"issue":"22","key":"10.1002\/14651858.CD013399.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Renteria AS Venugopal S Marcellino B Keyzner A Kremyanskaya M Najfeld V Dose-adjusted intensive chemotherapy is safe and tolerable in older patients with ph-negative acute lymphoblastic leukemia Blood. Conference: 60th Annual Meeting of the American Society of Hematology (ASH) Suppl 1 edition 5158 https:\/\/doi.org\/10.1182\/blood-2018-99-115634","DOI":"10.1182\/blood-2018-99-115634"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Sibai H Chen R Liu X Schimmer AD Schuh A Law A Anticoagulation prophylaxis with weight-adjusted enoxaparin reduces rates of venous thromboembolism in patients with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy Blood. Conference: 60th Annual Meeting of the American Society of Hematology (ASH) Suppl 1 edition 3974 10.1182\/blood-2018-99-119984","DOI":"10.1182\/blood-2018-99-119984"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16695","article-title":"Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated With asparaginase-based therapy","volume":"Online ahead of","author":"Sibai","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Sibai H Falcone U Datt Law A Sakurai N Saini L Wang TQ Anticoagulation prophylaxis in asparaginase-based therapy in adults with acute lymphoblastic leukemia Blood. Conference: 58th Annual Meeting of the American Society of Hematology (ASH) 22 edition 1453 10.1182\/blood.V128.22.1453.1453","DOI":"10.1182\/blood.V128.22.1453.1453"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.3747\/co.23.3077","article-title":"Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia","volume":"23","author":"Sibai","journal-title":"Current Oncology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Sibai HA Seki JT Sakurai N Schuh AC Yee KW Minden MD Safety and feasibility of anticoagulation prophylaxis with enoxaparin in acute lymphoblastic leukemia during asparaginase-based intensification therapy Journal of Clinical Oncology. Conference: the American Society of Clinical Oncology (ASCO) Suppl 15 edition 7048 10.1200\/jco.2015.33.15_suppl.7048","DOI":"10.1200\/jco.2015.33.15_suppl.7048"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Sibai HA Seki JT Wang T Saini L Stessman A Samuel J Safety of using escalated doses of enoxaparin prophylaxis in adults with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy Journal of Clinical Oncology. Conference: the American Society of Clinical Oncology (ASCO) Suppl 7 edition 141 10.1200\/jco.2016.34.7_suppl.141","DOI":"10.1200\/jco.2016.34.7_suppl.141"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0040|cit40","unstructured":"Umakanthan JM Maness LJ Luo J Kallam A Armitage JO Bierman P Safety and efficacy of enoxaparin prophylaxis in adults receiving peg-asparaginase containing induction regimens for acute lymphoblastic leukemia (ALL) Blood. Conference: 58th Annual Meeting of the American Society of Hematology (ASH) 22 edition 5154 10.1182\/blood.V128.22.5154.5154"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Underwood B Zhao Q Walker AR Mims AS Vasu S Behbehani G Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase Journal of Clinical Oncology. Conference:\u00a0American Society of Clinical Oncology (ASCO) Suppl 15 edition e18520 10.1200\/JCO.2019.37.15_suppl.e18520","DOI":"10.1200\/JCO.2019.37.15_suppl.e18520"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0042|cit42","unstructured":"Baile M Veiga A L\u00f3pez-Parra M S\u00e1nchez-Barba M Arratibel N Rodr\u00edguez B Peripherally inserted central catheter (PICC) related thrombosis in 230 patients with hematological malignancies. A 6 years single experience center International Society on Thrombosis and Haemostasis (ISTH) 2017 1160"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0043|cit43","unstructured":"Baile M Veiga A Lopez-Parra M Sanchez-Barba M Arratibel N Rodriguez B Peripherally inserted central catheter (PICC) related thrombosis in 230 patients with hematological malignancies. A 6 years single experience center Haematologica.\u00a022th Congress of the European Hematology Association. (EHA) 646 7"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/10428194.2019.1666380","article-title":"Risk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the national inpatient sample, 2011-2015","volume":"61","author":"Tang","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"10.1002\/14651858.CD013399.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1080\/10428194.2017.1312384","article-title":"Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy","volume":"58","author":"Barreto","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD013399.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7326\/0003-4819-76-3-112-6-423","article-title":"Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial","volume":"112","author":"Bern","year":"1990","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0047|cit47","unstructured":"Bern MM Lokich JJ Wallach SR Huberman M Tangen O Very low-dose warfarin prevents thrombosis of central vein catheters Journal of Clinical Oncology. Conference: Annual meeting of the American Society of Clinical Oncology (ASCO) 254"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Boban A Mikuli\u0107 M Serventi-Seiwerth R Ostoji\u0107 A Vrhovac R Durakovi\u0107 N Risk factors for thromboembolism in adult patients with acute lymphoblastic leukemia HemaSphere Issue S1 edition 771 10.1097\/01.HS9.0000564920.99794.0a","DOI":"10.1097\/01.HS9.0000564920.99794.0a"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/10428190290022164","article-title":"The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy - Report of a prospective randomized study","volume":"43","author":"Chojnowski","year":"2002","journal-title":"Leukemia & Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/pbc.22305","article-title":"Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"54","author":"Cohen","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"issue":"18","key":"10.1002\/14651858.CD013399.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1200\/jco.2005.10.192","article-title":"Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer","volume":"23","author":"Couban","year":"2005","journal-title":"Journal of\u00a0Clinical\u00a0Oncology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0052|cit52","unstructured":"Couban S Goodyear M Burnell M Dolan S Wasi P Macleod D A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer Blood. Conference:\u00a0 44th Annual Meeting of The American Society of Hematology\u00a0(ASH) 11\u00a0Suppl 1 edition Abstract 2769"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Freyer CW Ganetsky A Hughes ME Krause TM Timlin C Frey NV Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation: a single center characterization of risk factors and an assessment of supplementation practice Blood. Conference: 60th Annual Meeting of the American Society of Hematology (ASH) 2018 4023 10.1182\/blood-2018-99-112604","DOI":"10.1182\/blood-2018-99-112604"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1765239","article-title":"Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation","volume":"Online ahead of","author":"Freyer","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/annonc\/mdj059","article-title":"Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial","volume":"17","author":"Kretzschmar","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12887-017-0877-x","article-title":"TropicALL study: thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial","volume":"17","author":"Klaassen","year":"2017","journal-title":"BMC Pediatrics"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Kroll MH Ferrajoli A Cheng L Watkins JL Rodriguez MA Incidence rate of venous thromboembolism (VTE) and utilization of a VTE prophylaxis order set module in hospitalized patients with leukemia Blood. Conference: 55th Annual Meeting of the American Society of Hematology (ASH) Issue 21 edition 2013 2946 10.1182\/blood.V122.21.2946.2946","DOI":"10.1182\/blood.V122.21.2946.2946"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00280-013-2169-y","article-title":"Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study","volume":"72","author":"Lavau-Denes\u00a0","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0059|cit59","first-page":"3143","article-title":"Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients","volume":"25","author":"Magagnoli","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0060|cit60","unstructured":"Mazzucconi MG Gugliotta L Leone G De Stefano V Dragoni F Mattioli BM Antithrombin III infusion suppresses coagulation and fibrinolytic hyperactivation in adult acute lymphoblastic leukaemia (ALL) patients receiving E. coli l-asparaginase. A GIMEMA study International Society on Thrombosis and Haemostasis (ISTH) 1993 599"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00001721-199402000-00004","article-title":"Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study","volume":"5","author":"Mazzucconi","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0062|cit62","first-page":"67","article-title":"Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial","volume":"88","author":"\u00a0 Mille","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1650254","article-title":"Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (fragmin)","volume":"75","author":"Monreal","year":"1996","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0064|cit64","unstructured":"Napolitano M Valore L Saccullo G Malato A Vetro C Mitra ME Incidence and management of venous thrombosis in acute leukemia: A multicenter study Haematologica.\u00a019th Congress of the European Hematology Association (EHA) S61 2"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/10428194.2015.1046864","article-title":"Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study","volume":"57","author":"Napolitano","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Peterson EA Merkeley H Cavazzi E Chen L Lee AY The impact of a standardized protocol on thromboprophylaxis, venous thromboembolism and bleeding rates in hospitalized patients with hematological malignancies Blood. Conference: American Society of Hematology (ASH) Issue 21 edition 2013 1729 10.1182\/blood.V122.21.1729.1729","DOI":"10.1182\/blood.V122.21.1729.1729"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2257.1999.00250.x","article-title":"Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease","volume":"21","author":"Ratcliffe","journal-title":"Clinical & Laboratory Haematology"},{"issue":"18","key":"10.1002\/14651858.CD013399.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1200\/jco.2005.06.084","article-title":"Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients","volume":"23","author":"Verso","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"9663","key":"10.1002\/14651858.CD013399.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0140-6736(09)60205-1","article-title":"Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial","volume":"373","author":"Young","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1365-2141.1998.00732.x","article-title":"Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies","volume":"101","author":"Boraks","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies Annals of Oncology 20 12 1936 42 10.1093\/annonc\/mdp235 19567452","DOI":"10.1093\/annonc\/mdp235"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0072|cit72","unstructured":"Guillermo FC Aravena PC Fardella PD Araos DM Alfaro JI Flores CA Prophylaxis of venous thrombosis (VT) associated with central venous catheter (CVC) with low molecular weight heparin (LMWH) in hematologic malignancies Blood. Conference: 45th Annual Meeting of the American Society of Hematology (ASH) 11\u00a0Suppl 2 edition 122b"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1445-5994.2002.00171.x","article-title":"Minidose (1 Mg) warfarin as prophylaxis for central vein catheter thrombosis","volume":"32","author":"Heaton\u00a0","journal-title":"Internal Medicine Journal"},{"issue":"9","key":"10.1002\/14651858.CD013399.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1111\/j.1538-7836.2007.02660.x","article-title":"Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study","volume":"5","author":"Niers","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0075|cit75","unstructured":"Wiszniewski A Szopinski P Warzocha K Should we use venous thromboembolism prophylaxis in patients with haematological malignancies receiving chemotherapy? Journal of Thrombosis and Haemostasis.\u00a025th Congress of the International Society on Thrombosis and Haemostasis (ISTH) Suppl 13 edition 728 10.1111\/jth.12993"},{"issue":"10","key":"10.1002\/14651858.CD013399.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013399.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Aldoss I Martinez D Ji L Douer D The number of peg-asparaginase doses administered is a determinant of relapse risk in adult ALL treated with a pediatric-like regimen Blood. The American Society of Haematology (ASH) annual meeting 21 edition 3915 https:\/\/doi.org\/10.1182\/blood.V122.21.3915.3915","DOI":"10.1182\/blood.V122.21.3915.3915"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature Critical Reviews in Oncology\/Hematology 124 41 50 10.1016\/j.critrevonc.2018.02.003 29548485","DOI":"10.1016\/j.critrevonc.2018.02.003"},{"issue":"14","key":"10.1002\/14651858.CD013399.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa1816150","article-title":"Adjunctive intermittent pneumatic compression for venous thromboprophylaxis","volume":"380","author":"Arabi","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2003.10.013","article-title":"Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia","volume":"111","author":"Athale","year":"2003","journal-title":"Thrombosis Research"},{"issue":"7454","key":"10.1002\/14651858.CD013399.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"6\u00a0Suppl","key":"10.1002\/14651858.CD013399.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"364S","DOI":"10.1378\/chest.124.6_suppl.364s","article-title":"New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology","volume":"124","author":"Bauer","journal-title":"Chest"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/asheducation-2006.1.450","article-title":"New anticoagulants","volume":"1","author":"Bauer","journal-title":"Hematology. American Society of Hematology. Educational Program"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00421226","article-title":"Mechanism of the anticoagulant action of heparin","volume":"48","author":"Bj\u00f6rk","journal-title":"Molecular and cellular biochemistry"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013399.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1111\/jth.12028","article-title":"Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis","volume":"10","author":"Carrier","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1002\/14651858.CD013399.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1538-7836.2007.02383.x","article-title":"Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis","volume":"5","author":"Caruso","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0090|cit90","volume-title":"Available from\u00a0www.training.cochrane.org\/handbook","author":"Chaimani","year":"2019"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Chen R Liu X Maze D Chan SM Gupta V Risk of thrombosis in adult philadelphia-positive ALL treated with an asparaginase-free pediatric-inspired ALL regimen with imatinib Blood. Annual meeting of the American Society of hematology (ASH) Suppl 1 edition 1303 10.1182\/blood-2019-124117","DOI":"10.1182\/blood-2019-124117"},{"issue":"18","key":"10.1002\/14651858.CD013399.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"14961","DOI":"10.1074\/jbc.M011550200","article-title":"Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin","volume":"276","author":"Swanson","journal-title":"Journal of Biological Chemistry"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0093|cit93","unstructured":"Institute of Social and Preventive Medicine, University of Bern CINeMA: Confidence in Network Meta-Analysis [Software] 2017"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0095|cit95","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 http:\/\/ctep.cancer.gov"},{"issue":"12","key":"10.1002\/14651858.CD013399.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"De Bont","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD013399.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"De Stefano","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0099|cit99","volume-title":"Available from www.training.cochrane.org\/handbook","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0100|cit100","volume-title":"Available from www.training.cochrane.org\/handbook","author":"Deeks","year":"2019"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/0003-4819-146-4-200702200-00007","article-title":"Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients","volume":"146","author":"Dentali","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013399.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008500.pub4","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013399.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/jth.12683","article-title":"Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH","volume":"12","author":"Carrier","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1002\/14651858.CD013399.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2012-03-378901","article-title":"How I manage venous thromboembolism risk in hospitalized medical patients","volume":"120","author":"Dobromirski","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3747\/co.22.2586","article-title":"Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis","volume":"22","author":"Easaw","journal-title":"Current Oncology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4757-5985-3_4","article-title":"Anticoagulation proteins C and S","volume":"214","author":"\u00a0Vigano-D'Angelo","year":"1987","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"10","key":"10.1002\/14651858.CD013399.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2020.02.015","article-title":"Thromboembolism prophylaxis during l-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?","volume":"188","author":"Carrier","journal-title":"Thrombosis Research"},{"issue":"8","key":"10.1002\/14651858.CD013399.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11606-016-3603-8","article-title":"Effects of long-term low-molecular-weight heparin onfFractures and bone density in non-pregnant adults: a systematic review with meta-analysis","volume":"31","author":"Gajic-Veljanoski","journal-title":"Journal of General Internal Medicine"},{"issue":"18","key":"10.1002\/14651858.CD013399.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.119.041687","article-title":"Specific antidotes for direct oral anticoagulant reversal: case closed or cold case?","volume":"140","author":"Godier","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-017-1597-7","article-title":"The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia","volume":"45","author":"Grace","year":"2017","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0113|cit113","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEpro Guideline Development Tool [Software] 2015"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1992.tb00032.x","article-title":"Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group","volume":"49","author":"Gugliotta","year":"1992","journal-title":"European Journal of Haematology"},{"issue":"7650","key":"10.1002\/14651858.CD013399.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD013399.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"e26686","DOI":"10.1002\/pbc.26686","article-title":"Prolonged first-line peg-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-pharmacokinetics and antibody formation","volume":"64","author":"Henriksen","year":"2017","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0118|cit118","volume-title":"Available from\u00a0www.training.cochrane.org\/handbook","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0119|cit119","volume-title":"Available from www.training.cochrane.org\/handbook","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0120|cit120","volume-title":"Available from www.training.cochrane.org\/handbook","author":"Higgins","year":"2019"},{"issue":"6","key":"10.1002\/14651858.CD013399.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006468.pub6","article-title":"Anticoagulation for people with cancer and central venous catheters","author":"Kahale","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl\u00a02","key":"10.1002\/14651858.CD013399.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism phrophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013399.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","journal-title":"Thrombosis Research"},{"issue":"8","key":"10.1002\/14651858.CD013399.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1378\/chest.13-2993","article-title":"Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the Antithrombotic Therapy and the Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"146","author":"Kristiansen","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06209.x","article-title":"Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l-asparaginase: an in vitro study","volume":"134","author":"Kuhle","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0129|cit129","unstructured":"The MAGIC Foundation MAGICapp (Making Grade the Irresistible Choice authoring and publication platform) [Software] 2018"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2018.209528","article-title":"THROMBOTECT takes the lead","volume":"104","author":"Male","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines","volume":"22 Suppl 6","author":"Mandala","year":"2011","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1046\/j.1537-2995.1979.19580059818.x","article-title":"Antithrombin III in fresh frozen plasma, cryoprecipitate, and cryoprecipitate-depleted plasma","volume":"19","author":"Mintz","journal-title":"Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V83.2.386.386","article-title":"Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency","volume":"83","author":"Mitchell","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0134|cit134","first-page":"235","article-title":"Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study","volume":"90","author":"Mitchell","journal-title":"Thrombosis and Haemostasis"},{"issue":"24","key":"10.1002\/14651858.CD013399.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD013399.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/bloodadvances.2019000840","article-title":"DOACs vs LMWHs in Hospitalized Medical Patients: A Systematic Review and Meta-Analysis That Informed 2018 ASH Guidelines","volume":"4","author":"Neumann","journal-title":"DOACs vs LMWHs in Hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH Guidelines"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0049-3848(01)00286-9","article-title":"Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase\/prednisone administration","volume":"103","author":"Nowak-Gottl","year":"2001","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0138|cit138","volume-title":"Available from www.training.cochrane.org\/handbook","author":"Page","year":"2019"},{"issue":"24","key":"10.1002\/14651858.CD013399.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013399.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1055\/s-0039-1697027","article-title":"Effectiveness and safety of primary thromboprophylaxis in children with cancer: a systematic review of the literature and network meta-analysis","volume":"119","author":"Pelland-Marcotte\u00a0","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/ehm.11.86","article-title":"Treating venous thromboembolism in patients with cancer","volume":"5","author":"Piatek","year":"2012","journal-title":"Expert Review of Hematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0142|cit142","unstructured":"R Foundation for Statistical Computing R: A language and environment for statistical computing R Core Team 2019"},{"issue":"7","key":"10.1002\/14651858.CD013399.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatric Blood and Cancer"},{"issue":"22","key":"10.1002\/14651858.CD013399.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0146|cit146","volume-title":"Available from\u00a0www.training.cochrane.org\/handbook","author":"Reeves","year":"2019"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0147|cit147","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web) 2019"},{"issue":"11","key":"10.1002\/14651858.CD013399.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013399.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cam4.1094","article-title":"A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients","volume":"6","author":"Roininen","year":"2017","journal-title":"Cancer Medicine"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0150|cit150","unstructured":"Ryan R Synnot A Hill S Describing results Cochrane Consumers and Communication Group, available at:\u00a0http:\/\/cccrg.cochrane.org\/author-resources. Version 2.0"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Statistical Methods in Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"6","key":"10.1002\/14651858.CD013399.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a delphi consensus","volume":"17","author":"Halsey","journal-title":"Lancet Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013399.pub2-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009160.pub2","article-title":"Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters","author":"Schoot","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"22","key":"10.1002\/14651858.CD013399.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0158|cit158","volume-title":"Available from\u00a0www.training.cochrane.org\/handbook","author":"Sch\u00fcnemann","year":"2019"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0159|cit159","volume-title":"Available from\u00a0www.training.cochrane.org\/handbook","author":"Sch\u00fcnemann","year":"2019"},{"issue":"4","key":"10.1002\/14651858.CD013399.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bjh.15112","article-title":"BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy","volume":"180","author":"Sibson","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0162|cit162","doi-asserted-by":"crossref","unstructured":"Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies Leukemia & Lymphoma 61 6 1277 91 10.1080\/10428194.2020.1713321 31960713","DOI":"10.1080\/10428194.2020.1713321"},{"issue":"6","key":"10.1002\/14651858.CD013399.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.leu.2405051","article-title":"Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during l-asparaginase therapy","volume":"22","author":"Steiner","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.14898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0167|cit167","volume-title":"Available from\u00a0www.training.cochrane.org\/handbook","author":"Sterne","year":"2019"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia broup B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD013399.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"issue":"14","key":"10.1002\/14651858.CD013399.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD013399.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"714","DOI":"10.6004\/jnccn.2011.0062","article-title":"Venous thromboembolic disease","volume":"9","author":"Streiff","year":"2011","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"9","key":"10.1002\/14651858.CD013399.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2015.0133","article-title":"Cancer-Associated VenousThromboembolic Disease, Version 1.2015","volume":"13","author":"Chesney","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2011.09020.x","article-title":"Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008","volume":"157","author":"Toft","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12562","article-title":"Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"96","author":"Toft","year":"2016","journal-title":"European Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0177|cit177","first-page":"606","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD013399.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with l-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3109\/10428194.2010.537796","article-title":"Asparaginase revisited","volume":"52","author":"den Berg","journal-title":"Leukemia & Lymphoma"},{"issue":"10","key":"10.1002\/14651858.CD013399.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD013399.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/16078454.2020.1719726","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"25","author":"Wang","journal-title":"Hematology"},{"issue":"5","key":"10.1002\/14651858.CD013399.pub2-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013399.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: A new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1-2","key":"10.1002\/14651858.CD013399.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2004.07.016","article-title":"Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis","volume":"115","author":"Ziegler","year":"2005","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD013399.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on Hemostasis and Malignancy of the ISTH","volume":"18","author":"Zwicker","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1002\/14651858.CD013399.pub2-BIB0186|cit186","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013399","article-title":"Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia","author":"Rank","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:26:55Z","timestamp":1673368015000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013399.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":186,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013399.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]}}}